Physician profile
Nims Varadi
NPI 1528478492
$1,175.29
in general payments reported to CMS, 2019-2025
16 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2021: $66.22 · 2022: $164 · 2023: $482 · 2024: $165 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.75 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $193.14 | 2019-2023 | Xarelto |
| Abbvie INC. | $165.00 | 2021-2025 | Dalvance, Teflaro |
| Novartis Pharmaceuticals Corporation | $108.92 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.28 | 2019 | |
| Pfizer INC. | $101.64 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.46 | 2023-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $38.91 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $36.83 | 2022-2023 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $29.30 | 2023 | Inpefa |
| Stryker Corporation | $28.55 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alexion Pharmaceuticals, INC. | $24.49 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.96 | 2025 | Nuzyra |
| Boston Scientific Corporation | $18.74 | 2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $17.11 | 2023 | Verquvo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nims Varadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.